The present invention relates to compounds of the general formula (I) that
have activity as S1P receptor modulating agents and the use of such
compounds to treat diseases associated with inappropriate S1P receptor
activity. The compounds may be used as immunomodulators, e.g., for
treating or preventing diseases such as autoimmune and related immune
disorders including systemic lupus erythematosus, inflammatory bowel
diseases such as Crohn's disease and ulcerative colitis, type I diabetes,
uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis,
non-glomerular nephrosis, hepatitis, Behcet's disease,
glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia,
hepatitis and Wegner's granuloma; and for treating other conditions.